GlassScriptPhysician profile
Reem Salman
NPI 1972530046
$5,462.13
in general payments reported to CMS, 2019-2025
36 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,034 · 2020: $537 · 2021: $716 · 2022: $310 · 2023: $616 · 2024: $1,223 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,805 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,804.95 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $869.30 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $647.70 | 2019-2025 | |
| Novo Nordisk INC | $582.50 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $376.66 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $343.91 | 2019-2025 | Veozah |
| Abbvie INC. | $258.43 | 2021-2024 | Synthroid |
| Amgen INC. | $252.81 | 2019-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $227.92 | 2019-2025 | Gardasil 9, Gardasil, M-M-R II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.62 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $192.20 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Amarin Pharma, INC. | $160.65 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $156.10 | 2022-2025 | |
| Dexcom, INC. | $128.99 | 2021-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $108.38 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $104.95 | 2019-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $100.80 | 2025 | |
| Exact Sciences Corporation | $88.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $80.15 | 2019-2021 | |
| Sanofi Pasteur INC. | $61.35 | 2023 | |
| Abbott Laboratories | $52.29 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Actelion Pharmaceuticals US, INC. | $46.51 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.85 | 2022 | |
| Xeris Pharmaceuticals, INC. | $42.82 | 2023 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $41.97 | 2020-2021 | |
| Biogen, INC. | $38.63 | 2021 | |
| Amneal Pharmaceuticals LLC | $36.50 | 2022-2023 | Unithroid |
| Shire North American Group INC | $35.23 | 2019 | |
| Axsome Therapeutics, INC. | $21.52 | 2025 | Auvelity |
| Paratek Pharmaceuticals, INC. | $21.45 | 2025 | Nuzyra |
| Teva Pharmaceuticals USA, INC. | $19.38 | 2021 | |
| Antares Pharma, INC. | $18.48 | 2024 | Xyosted |
| Surgenex LLC | $17.15 | 2025 | Renograft, Surmatrix, Ardeograft |
| Takeda Pharmaceuticals U.S.A., INC. | $16.64 | 2025 | Trintellix |
| Edwards Lifesciences Corporation | $16.17 | 2021 | |
| Esperion Therapeutics, INC. | $15.79 | 2024 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $14.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reem Salman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.